For example, amyloid-beta and tau proteins are key biomarkers for Alzheimer’s disease, and pairing their analysis with cfDNA could help pinpoint early neurodegenerative changes. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.